Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.
Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China.
Front Immunol. 2023 Jan 24;14:1083523. doi: 10.3389/fimmu.2023.1083523. eCollection 2023.
The quantitative level and kinetics of neutralizing antibodies (NAbs) in individuals with Omicron breakthrough infections may differ from those of vaccinated individuals without infection. Therefore, we aimed to evaluate the difference in NAb levels to distinguish the breakthrough cases from the post-immunized population to identify early infected person in an outbreak epidemic when nasal and/or pharyngeal swab nucleic acid real-time PCR results were negative.
We collected 1077 serum samples from 877 individuals, including 189 with Omicron BA.2 breakthrough infection and 688 post-immunized participants. NAb titers were detected using the surrogate virus neutralization test, and were log(2)-transformed to normalize prior to analysis using Student's unpaired t-tests. Geometric mean titers (GMT) were calculated with 95% confidence intervals (CI). Linear regression models were used to identify factors associated with NAb levels. We further conducted ROC curve analysis to evaluate the NAbs' ability to identify breakthrough infected individuals in the vaccinated population.
The breakthrough infection group had a consistently higher NAb levels than the post-immunized group according to time since the last vaccination. NAb titers in the breakthrough infection group were 6.4-fold higher than those in the post-immunized group (GMT: 40.72 AU/mL and 6.38 AU/mL, respectively; <0.0001). In the breakthrough infection group, the NAbs in the convalescent phase were 10.9-fold higher than in the acute phase (GMT: 200.48 AU/mL and 18.46 AU/mL, respectively; p<0.0001). In addition, the time since infection, booster vaccination, and the time since last vaccination were associated with log(2)-transformed NAb levels in the breakthrough infection group. ROC curve analysis showed that ROC area was largest (0.728) when the cut-off value of log(2)-transformed NAb was 6, which indicated that NAb levels could identify breakthrough infected individuals in the vaccinated population.
Our study demonstrates that the NAb titers of Omicron BA.2 variant breakthrough cases are higher than in the post-immunized group. The difference in NAb levels could be used to identify cases of breakthrough infection from the post-immunized population in an outbreak epidemic.
奥密克戎突破性感染个体的中和抗体(NAb)的定量水平和动力学可能与未感染的接种个体不同。因此,我们旨在评估 NAb 水平的差异,以区分突破性感染病例和接种后人群,并在鼻和/或咽拭子核酸实时 PCR 结果为阴性时识别暴发疫情中的早期感染个体。
我们收集了 877 名个体的 1077 份血清样本,其中包括 189 名奥密克戎 BA.2 突破性感染个体和 688 名接种后个体。使用替代病毒中和试验检测 NAb 滴度,并使用学生非配对 t 检验对其进行对数(2)转换以进行分析前归一化。使用 95%置信区间(CI)计算几何均数滴度(GMT)。使用线性回归模型确定与 NAb 水平相关的因素。我们进一步进行了 ROC 曲线分析,以评估 NAb 识别接种人群中突破性感染个体的能力。
根据上次接种后的时间,突破性感染组的 NAb 水平始终高于接种后组。突破性感染组的 NAb 滴度比接种后组高 6.4 倍(GMT:40.72 AU/mL 和 6.38 AU/mL,均<0.0001)。在突破性感染组中,恢复期的 NAb 比急性期高 10.9 倍(GMT:200.48 AU/mL 和 18.46 AU/mL,均<0.0001)。此外,感染后时间、加强疫苗接种和上次接种后时间与突破性感染组的 log(2)转化 NAb 水平相关。ROC 曲线分析表明,当 log(2)转化的 NAb 的截断值为 6 时,ROC 面积最大(0.728),这表明 NAb 水平可以识别接种人群中的突破性感染个体。
我们的研究表明,奥密克戎 BA.2 变体突破性感染病例的 NAb 滴度高于接种后组。NAb 水平的差异可用于在暴发疫情中从接种后人群中识别突破性感染病例。